What is it about?
Disease progression and treatment response in a murine model of chronic obstructive pulmonary disease (COPD) were investigated using a preclinical hyperpolarized 129Xe (HPXe) MRI strategy. In the present study, the potential efficacy of Ethyl Pyruvate for COPD therapy is demonstrated as assessed by a non-invasive, translatable 129Xe MRI procedure.
Featured Image
Why is it important?
The feasibility of HPXe MRI for longitudinal assessment of disease progression and pharmacological therapy has been demonstrated in a mouse model of COPD. To the best of our knowledge, this is the first evidence of the therapeutic action of EP in a murine COPD model, as measured by HPXe MRI.
Perspectives
Read the Original
This page is a summary of: Treatment response of ethyl pyruvate in a mouse model of chronic obstructive pulmonary disease studied by hyperpolarized129Xe MRI, Magnetic Resonance in Medicine, September 2016, Wiley,
DOI: 10.1002/mrm.26458.
You can read the full text:
Contributors
The following have contributed to this page